Analyst firms · H.C. Wainwright · AKBA

H.C. Wainwright AKBA price target and rating history

Akebia Therapeutics Inc. (AKBA) · Health Care

H.C. Wainwright rates Akebia Therapeutics Inc. (AKBA) Buy with a $8 price target, as of its latest action on Jun 4, 2025. It has published 4 rating actions on AKBA since November 2021, including 1 upgrade and 1 downgrade.

Current rating
Buy
Price target
$8
Median target, all firms
Too few
Actions on AKBA
4

H.C. Wainwright price target on AKBA

$10$6$220222023202420252026
H.C. Wainwright price target on AKBA, each point a stated target, November 2021 to June 2025.

Every H.C. Wainwright rating on AKBA

Questions about H.C. Wainwright and AKBA

What is H.C. Wainwright's price target for AKBA?
H.C. Wainwright's latest stated price target for Akebia Therapeutics Inc. (AKBA) is $8, from its action on Jun 4, 2025.
What is H.C. Wainwright's rating on AKBA?
H.C. Wainwright rates AKBA Buy, a bullish rating, as of Jun 4, 2025.
When did H.C. Wainwright last change its view on AKBA?
On Jun 4, 2025, H.C. Wainwright resumes coverage at Buy, price target $8.

All H.C. Wainwright ratingsAKBA news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.